Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lazertinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Early research (Phase 1)Study completedNCT05076877
What this trial is testing

Lazertinib (JNJ-73841937) in Healthy Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 20
Early research (Phase 1)Study completedNCT05742594
What this trial is testing

Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 64
Early research (Phase 1)Study completedNCT04410081
What this trial is testing

(14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Who this might be right for
Healthy
Janssen Research & Development, LLC 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT05463224
What this trial is testing

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Who this might be right for
NSCLC
Sehhoon Park 150
Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Early research (Phase 1)Active Not RecruitingNCT04077463
What this trial is testing

Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 701
Testing effectiveness (Phase 2)Study completedNCT04965090
What this trial is testing

Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Metastatic Non Small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT05786430
What this trial is testing

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 87
Testing effectiveness (Phase 2)UnknownNCT05167851
What this trial is testing

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 68
Testing effectiveness (Phase 2)UnknownNCT05701384
What this trial is testing

Lazertinib 160mg in EGFR T790M NSCLC

Who this might be right for
Lung Cancer Stage IVEGFR T790M
Samsung Medical Center 117
Testing effectiveness (Phase 2)UnknownNCT05338619
What this trial is testing

Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Who this might be right for
Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer
Sung Yong Lee 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT05601973
What this trial is testing

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
ETOP IBCSG Partners Foundation 60
Not applicableStudy completedNCT05862194
What this trial is testing

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Yuhan Corporation 534
Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Testing effectiveness (Phase 2)Looking for participantsNCT07586202
What this trial is testing

Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 68
Large-scale testing (Phase 3)Active Not RecruitingNCT04487080
What this trial is testing

Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 1,074
Testing effectiveness (Phase 2)UnknownNCT06020989
What this trial is testing

Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 129
Testing effectiveness (Phase 2)Study completedNCT05299125
What this trial is testing

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Metastatic Non-small Cell Lung Cancers
Latin American Cooperative Oncology Group 54
Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40